Literature DB >> 17627792

Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.

J A Moreno-Romero1, S Segura, J M Mascaró, S E Cowper, M Julià, E Poch, A Botey, C Herrero.   

Abstract

Nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy is a rare fibrotic condition that presents in patients with a history of renal disease. The aetiology is unknown, but it has recently been proposed that gadolinium, a paramagnetic contrast agent, may be a trigger of this disease. We report three patients with NSF with a history of use of gadolinium in magnetic resonance angiography a few weeks before the onset of symptoms. In the future, gadolinium should probably be avoided as much as possible in renal insufficiency patients until its role in the development of NSF is clarified.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627792     DOI: 10.1111/j.1365-2133.2007.08067.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  Scan-stratified case-control sampling for modeling blood-brain barrier integrity in multiple sclerosis.

Authors:  Gina-Maria Pomann; Elizabeth M Sweeney; Daniel S Reich; Ana-Maria Staicu; Russell T Shinohara
Journal:  Stat Med       Date:  2015-05-04       Impact factor: 2.373

Review 2.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

3.  Predicting breakdown of the blood-brain barrier in multiple sclerosis without contrast agents.

Authors:  R T Shinohara; J Goldsmith; F J Mateen; C Crainiceanu; D S Reich
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-22       Impact factor: 3.825

4.  Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

Authors:  B J Edwards; A E Laumann; B Nardone; F H Miller; J Restaino; D W Raisch; J M McKoy; J A Hammel; K Bhatt; K Bauer; A T Samaras; M J Fisher; C Bull; E Saddleton; S M Belknap; H S Thomsen; E Kanal; S E Cowper; A K Abu Alfa; D P West
Journal:  Br J Radiol       Date:  2014-10       Impact factor: 3.039

5.  Is it time to relax nephrogenic systemic fibrosis guidelines and safely offer magnetic resonance imaging to more patients?

Authors:  Saif Al-Chalabi; Constantina Chrysochou; Philip A Kalra
Journal:  Quant Imaging Med Surg       Date:  2019-11

6.  Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.

Authors:  Javier Perez-Rodriguez; Shenghan Lai; Benjamin D Ehst; Derek M Fine; David A Bluemke
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

Review 7.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

Review 8.  Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature.

Authors:  Jeffrey P Weigle; Dale R Broome
Journal:  Skeletal Radiol       Date:  2008-03-07       Impact factor: 2.199

9.  Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.

Authors:  Zhitong Zou; Lin Ma
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

10.  An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.

Authors:  Bin Zhang; Long Liang; Wenbo Chen; Changhong Liang; Shuixing Zhang
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.